Boston Partners Has $779,781,000 Position in Gilead Sciences, Inc. (GILD)

Boston Partners Has $779,781,000 Position in Gilead Sciences, Inc. (GILD)

Boston Partners boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 51.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,855,682 shares of the biopharmaceutical company’s stock after buying an additional 3,358,289 shares during the period. Gilead Sciences accounts for 1.1% of Boston Partners’ portfolio, making the stock its 10th largest position. Boston Partners’ holdings in Gilead Sciences were worth $779,781,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale increased its position in shares of Gilead Sciences by 16.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,094,601 shares of the biopharmaceutical company’s stock worth $85,334,000 after buying an additional 153,070 shares during the period. BancorpSouth Inc increased its stake in shares of Gilead Sciences by 3.3% in the third quarter. BancorpSouth Inc now owns 18,969 shares of the biopharmaceutical company’s stock valued at $1,501,000 after buying an additional 611 shares during the last quarter. Garcia Hamilton & Associates LP DE increased its stake in shares of Gilead Sciences by 6.0% in the third quarter. Garcia Hamilton & Associates LP DE now owns 47,265 shares of the biopharmaceutical company’s stock valued at $3,740,000 after buying an additional 2,666 shares during the last quarter. Frontier Investment Mgmt Co. increased its stake in shares of Gilead Sciences by 43.8% in the third quarter. Frontier Investment Mgmt Co. now owns 66,793 shares of the biopharmaceutical company’s stock valued at $5,285,000 after buying an additional 20,333 shares during the last quarter. Finally, Palisade Capital Management LLC NJ increased its stake in shares of Gilead Sciences by 69.6% in the third quarter. Palisade Capital Management LLC NJ now owns 10,600 shares of the biopharmaceutical company’s stock valued at $839,000 after buying an additional 4,350 shares during the last quarter. 74.62% of the stock is owned by institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 72.34 on Monday. The firm’s 50-day moving average is $73.03 and its 200-day moving average is $76.36. The company has a market capitalization of $95.30 billion, a price-to-earnings ratio of 6.69 and a beta of 1.11. Gilead Sciences, Inc. has a 12-month low of $69.78 and a 12-month high of $103.10.

Several brokerages recently commented on GILD. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Sunday, November 6th. Cowen and Company set a $120.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, October 23rd. BMO Capital Markets reaffirmed a “market perform” rating and set a $88.00 target price on shares of Gilead Sciences in a report on Friday, January 13th. Robert W. Baird reaffirmed an “outperform” rating and set a $100.00 target price on shares of Gilead Sciences in a report on Wednesday, December 21st. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $87.00 target price (down previously from $90.00) on shares of Gilead Sciences in a report on Wednesday, January 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $95.23.

In other news, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $74.86, for a total value of $7,860,300.00. Following the completion of the transaction, the director now directly owns 121,761 shares in the company, valued at $9,115,028.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the completion of the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at $235,814,224.47. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Related posts

Leave a Comment